

**Question for written answer E-002527/2026/rev.1
to the Commission**

Rule 144

Majdouline Sbai (Verts/ALE), Marie Toussaint (Verts/ALE), Mélissa Camara (Verts/ALE), David Cormand (Verts/ALE), Mounir Satouri (Verts/ALE), Tilly Metz (Verts/ALE)

Subject: Anti-dumping complaint against Chinese imports of 6-aminopenicillanic acid, a key ingredient for producing amoxicillin

On 28 May 2026, the pharmaceuticals company Sandoz lodged an anti-dumping complaint concerning Chinese imports of 6-aminopenicillanic acid, a key ingredient in the production of amoxicillin, the world's most widely used antibiotic¹.

Commissioner Ribera has stated that: 'The Critical Medicines Act is about improving a secure supply of vital medicines in Europe.'² With the trilogue agreement expected to be adopted shortly, we call on the Commission to act without delay to protect our amoxicillin producers from Chinese competition.

The Commission's respect for confidentiality obligations from the moment the complaint is received, even before any investigation may be opened is laudable.

1. Could the Commission nevertheless confirm and publish the studies or reports carried out by its services on Chinese commercial practices in the medicines sector, and more specifically regarding antibiotics, as well as on the situation in the amoxicillin supply chain (including components thereof) and the anticipated risks of supply disruptions?
2. What approach does it intend to take to address the increasing number of requests for investigations from European companies across all sectors, in order to ensure swifter processing and a more effective defence against unfair practices? Does it intend to review the current timetable?

Submitted: 17.6.2026

¹ https://www.lemonde.fr/economie/article/2026/06/01/depuis-la-derniere-usine-europeenne-de-penicilline-sandoz-exhorte-l-europe-a-agir-face-a-la-chine_6696011_3234.html?srltid=AfmBOoo6MrcfuyO0Qt5JPQQiEVNssM32_8zmCjbHTj9JPG3pieBx4Axc.

² https://ec.europa.eu/commission/presscorner/detail/en/ip_25_733.